LLYStockLilly(Eli) & Co
Verdicts genuinely change. Free email alert the moment LLY's does — no target price to set, unlike a price alert.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Lilly(Eli) & Co (LLY) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 433 compliant Healthcare stocks we track. See compliant Healthcare stocks →
How the status reached this point
Compliant · status tracked since Nov 17, 2026
No change to LLY’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
Read once a day from our own screen, last on Nov 18, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $1.33T as of 2026-11-18. At the 2026-11-19 close it is about $1.29T (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 3.8% (3.7% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 0.4% (0.4% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.
Business activity: cleared (no excluded categories detected)
AAOIFI Pass from the screen of 2026-09-09 2 of 2 ratios pass
This Pass was decided by the screen of 2026-09-09. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.72% | 30.00% | Pass(26.3pp buffer) |
| Interest-bearing investments | 0.37% | 30.00% | Pass(29.6pp buffer) |
Usmani Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 33.43% | 33.00% | Fail(0.4pp over) |
| Interest-bearing investments | 3.30% | 33.00% | Pass(29.7pp buffer) |
| Non-liquid assets | 81.78% | at least 20.00% | Pass(61.8pp above the floor) |
MSCI Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 33.43% | 33.33% | Fail(0.1pp over) |
| Cash + interest-bearing securities | 3.30% | 33.33% | Pass(30.0pp buffer) |
| Accounts receivable | 18.22% | 33.33% | Pass(15.1pp buffer) |
FTSE Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 33.43% | 33.33% | Fail(0.1pp over) |
| Cash + interest-bearing securities | 3.30% | 33.33% | Pass(30.0pp buffer) |
| Accounts receivable | 18.22% | 50.00% | Pass(31.8pp buffer) |
Dow Jones Islamic Market Pass from the screen of 2026-09-09 3 of 3 ratios pass
This Pass was decided by the screen of 2026-09-09. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.32% | 33.00% | Pass(27.7pp buffer) |
| Cash + interest-bearing securities | 0.52% | 33.00% | Pass(32.5pp buffer) |
| Accounts receivable | 2.37% | 33.00% | Pass(30.6pp buffer) |
S&P Shariah Pass from the screen of 2026-09-09 3 of 3 ratios pass
This Pass was decided by the screen of 2026-09-09. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.65% | 33.00% | Pass(27.3pp buffer) |
| Cash + interest-bearing securities | 0.56% | 49.00% | Pass(48.4pp buffer) |
| Accounts receivable | 2.52% | 49.00% | Pass(46.5pp buffer) |
MSCI M-Series Pass from the screen of 2026-09-09 3 of 3 ratios pass
This Pass was decided by the screen of 2026-09-09. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.65% | 33.33% | Pass(27.7pp buffer) |
| Cash + interest-bearing securities | 0.56% | 33.33% | Pass(32.8pp buffer) |
| Accounts receivable | 3.08% | 49.00% | Pass(45.9pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from LLY's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $65.2B | 2025-12-31 | Revenues |
| Interest-bearing debtShort and long-term borrowings | $49.5B | 2026-09-30 | LongTermDebtNoncurrent, DebtCurrent |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $4.9B | 2026-09-30 | CashAndCashEquivalentsAtCarryingValue |
| Total assetsBalance sheet total | $148.1B | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $1.3T | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $837.6B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $889.6B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | not measured | — | — |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-10-29, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-12, period ended 2025-12-31. Screened 2026-11-18.
-
Total assets$148.1B
Assets· period ended 2026-09-30 · 10-Q filed 2026-10-29 -
Interest-bearing debt$49.5B
LongTermDebtNoncurrent$47.0B · period ended 2026-09-30 · 10-Q filed 2026-10-29DebtCurrent$2.5B · period ended 2026-09-30 · 10-Q filed 2026-10-29 -
Cash and interest-bearing securities$4.9B
CashAndCashEquivalentsAtCarryingValue· period ended 2026-09-30 · 10-Q filed 2026-10-29 -
Receivables$22.1B
AccountsReceivableNetCurrent· period ended 2026-09-30 · 10-Q filed 2026-10-29 -
Revenue$65.2B
Revenues· period ended 2025-12-31 · 10-K filed 2026-02-12 -
Market cap$1.3TMarket quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-18 · not a filing figure, so no link
6 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.
What changed, and when
Verdict history for LLY. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for LLY has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
Revenue by business segment
How LLY’s $65.2B of revenue for the fiscal year 2025-01-01 to 2025-12-31 splits across what it sells, as the company tags it in its own 10-K.
| Segment | Share | Revenue |
|---|---|---|
| Net product revenue | 93.5% | $61.0B |
| Collaboration and other revenue | 6.5% | $4.2B |
These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.
Source: 10-K filed 2026-02-12 (accession 0000059478-26-000013), read from its XBRL on SEC EDGAR. Shares are of total revenue; subtotals and overlapping cuts the filing also tags are left out, so the lines add up to the total.
Shariah-compliant alternatives
Compliant companies in Drug Manufacturers - General listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| JNJJohnson & Johnson | $658.0B | — |
| ABBVAbbvie Inc | $467.4B | — |
| MRKMerck & Co Inc | $371.7B | $132.82-3.60% |
| NVSNovartis AG - ADR | $306.5B | — |
| AZNAstrazeneca plc - ADR | $252.0B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold LLY
27 of the 246 funds whose filed holdings we currently hold own LLY shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns LLY.
Shariah funds| Fund | LLY in fund | Fund compliant by weight |
|---|---|---|
| MNZL Manzil Russell Halal USA Broad Market ETF | 3.26% | 88% |
| SPUS SP Funds S&P 500 Sharia Industry Exclusions ETF | 2.35% | 79% |
| HLAL Wahed FTSE USA Shariah ETF | 2.32% | 72% |
Widely held U.S. index funds. If you own one, you own LLY through it. None of them is a Shariah fund; the last column is our look-through of each.
| Fund | LLY in fund | Fund compliant by weight |
|---|---|---|
| IWF iShares Russell 1000 Growth ETF | 2.84% | 69% |
| VUG VANGUARD GROWTH INDEX FUND | 2.81% | 63% |
| SPY | 1.47% | 56% |
| VOO VANGUARD 500 INDEX FUND | 1.47% | 56% |
| SPYM State Street(R) SPDR(R) Portfolio S&P 500(R) ETF | 1.47% | 56% |
| IVV iShares Core S&P 500 ETF | 1.47% | 56% |
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 1.30% | 54% |
| SCHB Schwab U.S. Broad Market ETF | 1.23% | 53% |
| RSP Invesco S&P 500 Equal Weight ETF | 0.20% | 44% |
| Fund | LLY in fund | Fund compliant by weight |
|---|---|---|
| BWTG Brendan Wood TopGun ETF | 4.08% | 66% |
| TWCCX Ultra Fund | 3.46% | 59% |
| REDWX GreenFi Redwood Fund | 3.27% | not computed |
| PJFV PGIM Jennison Focused Value ETF | 2.71% | 50% |
| PEQZX PGIM Jennison Blend Fund | 2.04% | 47% |
| PEPS Parametric Equity Plus ETF | 1.80% | 54% |
| GSUS Goldman Sachs MarketBeta U.S. Equity ETF | 1.51% | 55% |
| AVTM Avantis Total Equity Markets ETF | 1.51% | 43% |
| QWLD State Street(R) SPDR(R) MSCI World StrategicFactors(SM) ETF | 1.45% | 52% |
| GURU Global X Guru Index ETF | 1.27% | 43% |
5 more funds
Sorted by LLY’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names LLY once, so a bond is not counted as the shares; 3 more funds name LLY in a way we cannot separate from its bonds, and are not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $6,276M | 1.8% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $5,448M | 0.6% | 2026-09-30 |
| Israel Englander | Millennium Management | $1,022M | 0.3% | 2026-09-30 |
| Jeremy Grantham | GMO | $872M | 1.9% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $719M | 0.3% | 2026-09-30 |
| Saturna Capital | Amana Mutual Funds Trust | $506M | 5.9% | 2026-09-30 |
| Polen Capital | Polen Capital Management | $427M | 4.6% | 2026-09-30 |
| Mairs & Power | Mairs & Power | $365M | 3.4% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $182M | 0.2% | 2026-09-30 |
| Jensen Investment Management | Jensen Investment Management | $128M | 4.0% | 2026-09-30 |
| Cathie Wood | ARK Investment Management | $125M | 0.7% | 2026-09-30 |
| Ray Dalio | Bridgewater Associates | $110M | 0.5% | 2026-09-30 |
| Ron Baron | Baron Capital (BAMCO) | $106M | 0.2% | 2026-09-30 |
| Larry Robbins | Glenview Capital Management | $67M | 1.1% | 2026-09-30 |
| Jefferies | Jefferies Financial Group | $62M | 0.5% | 2026-09-30 |
| Paul Tudor Jones | Tudor Investment Corp | $55M | 0.1% | 2026-09-30 |
| Frank Sands | Sands Capital Management | $49M | 0.2% | 2026-09-30 |
| Dodge & Cox | Dodge & Cox | $46M | 0.0% | 2026-09-30 |
| Joel Greenblatt | Gotham Asset Management | $34M | 0.1% | 2026-09-30 |
| Mario Gabelli | GAMCO Investors | $31M | 0.3% | 2026-09-30 |
| George Soros | Soros Fund Management | $26M | 0.3% | 2026-09-30 |
| Wahed Invest | Wahed Invest LLC | $23M | 2.4% | 2026-06-30 |
| Azzad Asset Management | Azzad Asset Management | $6M | 0.6% | 2026-09-30 |
| Stanley Druckenmiller | Duquesne Family Office | $4M | 0.1% | 2026-09-30 |
| Sallie Krawcheck | Ellevest | $4M | 0.4% | 2026-09-30 |
| Caxton Associates | Caxton Associates LLP | $3M | 0.1% | 2026-09-30 |
| Robert Bruce | Bruce & Co. | $2M | 0.6% | 2026-09-30 |
| Jeff Auxier | Auxier Asset Management | $1M | 0.1% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $1M | 0.0% | 2026-09-30 |
| Bill Nygren | Harris Associates (Oakmark) | $0M | 0.0% | 2026-09-30 |
| Torray Investment Partners | Torray Investment Partners | $0M | 0.1% | 2026-09-30 |
| David Katz | Matrix Asset Advisors | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 50.70 | NEUTRAL |
| Stochastic %K (14) | 15.00 | BUY |
| CCI (20) | -32.57 | NEUTRAL |
| Williams %R (14) | -85.00 | BUY |
| MACD (12,26,9) | -9.84 | SELL |
| ROC (10) | -0.73 | SELL |
| Momentum (10) | -9.93 | SELL |
| EMA (10) | 1395.57 | SELL |
| SMA (10) | 1408.09 | SELL |
| EMA (20) | 1370.06 | BUY |
| SMA (20) | 1379.08 | BUY |
| EMA (30) | 1340.70 | BUY |
| SMA (30) | 1330.46 | BUY |
| EMA (50) | 1296.79 | BUY |
| SMA (50) | 1260.97 | BUY |
| EMA (100) | 1231.74 | BUY |
| SMA (100) | 1222.33 | BUY |
| EMA (200) | 1145.37 | BUY |
| SMA (200) | 1113.36 | BUY |
About Lilly(Eli) & Co
Healthcare · Drug Manufacturers - General
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-10-28
Stop 1271.18 Now 1382.75 Target 1326.26
🟢 STRONG BUY SETUP
Strong confluence across multiple layers — outperforming the market by 15.7%, RSI in healthy zone, Wall Street broadly bullish. High conviction entry. Use `!plan LLY [entry] [stop] [target]` to size the position properly.
Scores: 4 bullish / 1 bearish
Average — needs more confirmation before sizing up
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 64 |
| ⏰ 4H | BEARISH | 76 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
BEARISH 0 buys · 2 sells
Recent: Hakim Anat sold 11875 sh @ $1190.00 (2026-08-07); Zakrowski Donald A sold 1526 sh @ $1185.01 (2026-08-10)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.